natgillin/translations-raw huggingface dataset:
After proper training in injection technique, patients may self-inject with Hulio if their physician determines that it is appropriate and with medical follow-up as necessary. 
Bolniki, ki se naučijo pravilnega postopka injiciranja, si zdravilo Hulio lahko injicirajo sami, če zdravnik presodi, da je to primerno, in je zagotovljeno ustrezno medicinsko spremljanje.
• Do not give Hulio to children with enthesitis-related arthritis and Crohn's disease below the age of 6 years. 
• Zdravila Hulio ne smete dati otroku z artritisom, povezanim z entezitisom, in s Crohnovo boleznijo, če je star manj kot 6 let.
Neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to the initiation of Hulio therapy and regularly during treatment to assess for pre-existing or developing central demyelinating disorders. 
Pri bolnikih z neinfekcijskim intermediarnim uveitisom je treba pred začetkom zdravljenja z zdravilom Hulio in redno med zdravljenjem opravljati nevrološko oceno, da se oceni že obstoječe ali razvijajoče se demielinizirajoče bolezni osrednjega živčevja.
• DO NOT throw the sharps container in your household bin. 
• Vsebnika za ostre predmete NE ODLAGAJTE v koš za gospodinjske odpadke.
Partially peel open the needle package from the end closest to the yellow syringe connector. 
Delno odprite ovojnino igle tako, da jo odlepite od konca, ki je najbližji rumenemu konektorju za brizgo.
Adalimumab treated patients had significantly greater improvement at week 12 which was maintained through week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL). 
Bolniki, ki so dobivali adalimumab, so imeli po 12 tednih statistično značilno večje izboljšanje (ki se je ohranilo do 24. tedna) glede na SF-36 in ASQoL (Vprašalnik o kakovosti življenja pri ankilozirajočem spondilitisu - Ankylosing Spondylitis Quality of Life Questionnaire).
If you forget to give yourself an injection, you should inject the next dose of Hulio as soon as you remember. 
Če si pozabite dati injekcijo, si morate naslednji odmerek zdravila Hulio injicirati, čim se spomnite.
Administration of Hulio should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled. 
Če se bolniku pojavi nova resna okužba ali sepsa, je treba uporabo zdravila Hulio prekiniti in uvesti ustrezno protimikrobno ali protimikotično zdravljenje, dokler okužba ni obvladana.
Do not use Hulio 
Ne uporabljajte zdravila Hulio
This risk may increase if your child lung function is reduced. 
Tveganje je lahko večje, če ima vaš otrok oslabljeno delovanje pljuč.
Be careful to place the pen so that it will not inject into your fingers holding the injection site. 
Pazite, da injekcijski peresnik postavite tako, da zdravila ne boste injicirali v prste, ki držijo injekcijsko mesto.
• There have been very rare cases of certain kinds of cancer in children and adults taking adalimumab or other TNFα blockers. 
• Pri otrocih in odraslih, ki so jemali adalimumab ali druge zaviralce TNFα, so se pojavili zelo redki primeri določenih vrst raka.
In controlled and open label adult and paediatric studies with adalimumab, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis candidiasis, aspergillosis and listeriosis). 
V kontroliranih in odprtih študijah pri odraslih in otrocih z adalimumabom so poročali o resnih okužbah (vključno s smrtno nevarnimi okužbami, ki so se pojavile redko), med katerimi so bile tuberkuloza (tudi miliarna in zunajpljučna) in invazivne oportunistične okužbe (npr. diseminirana ali zunajpljučna histoplazmoza, blastomikoza, kokcidioidomikoza, pnevmocistoza, kandidoza, aspergiloza in listerioza).
MARKETING AUTHORISATION NUMBER(S) EU/1/18/1319/007 2 vials (2 packs of 1) 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/18/1319/007 2 viali (2 pakiranji s po 1 vialo)
Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in rodents. 
Z adalimumabom niso bile narejene niti raziskave kancerogenosti niti standardne ocene plodnosti ter poporodne toksičnosti, in sicer zato, ker ni ustreznih modelov za protitelo z omejeno navzkrižno reaktivnostjo z glodavskim TNF, in zaradi nastanka nevtralizirajočih protiteles pri glodavcih.
If you accidentally inject Hulio more frequently than you should, call your doctor or pharmacist and explain that you have taken more than required. 
Če ste uporabili večji odmerek zdravila Hulio, kot bi smeli Če pomotoma injicirate zdravilo Hulio pogosteje, kot bi morali, se posvetujte s svojim zdravnikom ali farmacevtom in mu povejte, da ste uporabili večji odmerek, kot je potreben.
p-value 
P-vrednostb
During the controlled portions of pivotal adalimumab trials in adults of at least 12 weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per 1,000 patient-years among 5,291 adalimumab treated patients versus a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control patients (median duration of treatment was 4.0 months for adalimumab and 3.8 months for control-treated patients). 
V kontroliranih delih osrednjih preskušanj adalimumaba pri odraslih, ki so trajala vsaj 12 tednov, pri bolnikih z zmerno do hudo aktivnim revmatoidnim artritisom, ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS, psoriatičnim artritisom, psoriazo, hidradenitis suppurativa, Crohnovo boleznijo, ulceroznim kolitisom in uveitisom so malignome (razen limfoma in nemelanomskega kožnega raka) opažali z deležem (95-% interval zaupanja) 6,8 (4,4; 10,5) na 1000 bolnikov-let med 5291 bolniki, ki so prejemali adalimumab, v primerjavi s 6,3 (3,4; 11,8) na 1000 bolnikov-let med 3444 kontrolnimi bolniki (pri prvih je zdravljenje mediano trajalo 4,0 meseca in pri drugih 3,8 meseca).
If new areas of damaged skin appear during or after treatment or if existing marks or areas of damage change appearance, tell your doctor. 
Če se vam med zdravljenjem ali po njem pojavijo nova območja poškodovane kože ali če se spremeni videz obstoječih znamenj ali poškodovanih območij, morate to povedati zdravniku.
• If your child is pregnant, thinks she may be pregnant or is planning to have a baby, ask her doctor for advice about taking this medicine. 
Če je vaš otrok noseč, meni, da bi lahko bil noseč ali načrtuje zanositev, se z otrokovim zdravnikom posvetujte o uporabi tega zdravila.
1 sterile injection syringe 
1 sterilna injekcijska brizga
Table 1: Hulio Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis 
Preglednica 1: Odmerjanje zdravila Hulio pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom
PGA: Clear/minimalc a MTX = methotrexate b P=0.027, adalimumab 0.8 mg/kg versus MTX c P=0.083, adalimumab 0.8 mg/kg versus MTX 
PASI 75b PGA: čisto/minimalnoc a MTX = metotreksat b P = 0,027, adalimumab 0,8 mg/kg v primerjavi z MTX c P = 0,083, adalimumab 0,8 mg/kg v primerjavi z MTX
If your child takes Hulio the risk of getting lymphoma, leukaemia, or other cancers may increase. 
Če vaš otrok uporablja zdravilo Hulio, se mu lahko poveča tveganje za pojav limfoma, levkemije ali drugih vrst raka.
Hulio is used to treat polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 17 years, and enthesitis-related arthritis in children and adolescents aged 6 to 17 years. 
Zdravilo Hulio se uporablja za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa pri otrocih in mladostnikih, starih 2 do 17 let, in artritisa, povezanega z entezitisom, pri otrocih in mladostnikih starih od 6 do 17 let.
The rate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%) in the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32 (9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). 
Razmerje nosečnosti, ki so se končale vsaj z enim živorojenim otrokom z večjim defektom ob rojstvu je bilo 6/69 (8,7 %) pri nosečnicah, zdravljenih z adalimumabom z RA, in 5/74 (6,8 %) pri nezdravljenih nosečnicah z RA (neprilagojeno razmerje obetov 1.31, 95 % interval zaupanja 0.38-4.52), ter 16/152 (10,5 %) pri nosečnicah, zdravljenih z adalimumabom s CB, in 3/32 (9,4 %) pri nezdravljenih nosečnicah s CB (neprilagojeno razmerje obetov 1.14, 95 % interval zaupanja 0.31-4.16).
No ALT elevations ≥3 X ULN occurred in the Phase 3 trial of adalimumab in paediatric patients with plaque psoriasis. 
Do nobenih zvišanj ALT ≥ 3 × ULN ni prišlo v preskušanju faze 3 z adalimumabom pri pediatričnih bolnikih s psoriazo v plakih.
Peel the clear plastic just far enough to expose the white plunger rod, but DO NOT take the syringe out of the package. 
Odlepite prozorno plastiko ravno toliko, da odkrijete beli nosilec bata, vendar brizge NE vzemite iz ovojnine.
Hulio is administered by injection under the skin (subcutaneous use). 
Zdravilo Hulio se injicira pod kožo (subkutana uporaba).
Hulio 40 mg solution for injection in pre-filled pen EU/1/18/1319/004 
Hulio 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku EU/1/18/1319/004
At week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically relevant decrease in HS-related skin pain (see Table 17). 
V 12. tednu je statistično pomembno večji delež bolnikov v študiji HS-II občutil klinično pomembno zmanjšanje bolečine kože, povezane s HS (glejte preglednico 17).
Of 342 subjects originally randomised to adalimumab monotherapy or adalimumab/methotrexate combination therapy who entered the open-label extension study, 171 subjects completed 10 years of adalimumab treatment. 
Od 342 oseb, ki so bile od začetka randomizirane na monoterapijo z adalimumabom ali kombinirano zdravljenje z adalimumabom/metotreksatom in so bile vključene v odprto podaljšano študijo, je 171 bolnikov zaključilo 10-letno zdravljenje z adalimumabom.
If you received Hulio while you are pregnant, your baby may be at higher risk for getting an infection for up to about five months after the last dose you received during pregnancy. 
Če ste prejemali zdravilo Hulio med nosečnostjo, obstaja večje tveganje, da bo vaš otrok dobil takšno okužbo do približno pet mesecev po zadnjem odmerku, ki ste ga prejeli med nosečnostjo.
• If your child is about to have surgery or dental procedures, tell your child's doctor that your child is taking Hulio. 
• Če bo vaš otrok imel kirurški poseg ali poseg na zobeh, otrokovemu zdravniku povejte, da jemlje zdravilo Hulio.
Among patients who were at least partial responders at week 12, and who received continuous weekly adalimumab therapy, the HiSCR rate at week 48 was 68.3% and at week 96 was 65.1%. 
Med bolniki z vsaj delnim odzivom v 12. tednu, ki so prejemali neprekinjeno terapijo adalimumaba vsak teden, je bila stopnja kliničnega odziva (HiSCR) v 48. tednu 68,3 % in v 96. tednu 65,1 %.
Myocardial infarction1), arrhythmia, congestive heart failure 
pogosti tahikardija občasni miokardni infarkt1), aritmija, kongestivno srčno popuščanje redki srčni zastoj
The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the percent of patients who achieved an ACR 20 response at week 24 or 26. 
Primarna končna točka v študijah revmatoidnega artritisa I, II in III ter sekundarna končna točka v študiji revmatoidnega artritisa IV je bila odstotek bolnikov, ki so po 24 oz. 26 tednih dosegli odziv ACR 20.
In paediatric uveitis, there is no experience in the treatment with Hulio without concomitant treatment with methotrexate. 
Izkušenj z zdravilom Hulio pri zdravljenju uveitisa pri pediatričnih bolnikih brez sočasnega zdravljenja z metotreksatom ni.
o DO NOT use the syringe if the medication is not near the Fill Marker. 
◦ Injekcijske brizge NE uporabljajte, če zdravilo ni v bližini oznake napolnjenosti.
The safety and efficacy of adalimumab were assessed in two randomized, double-blind placebo controlled studies in patients with non-radiographic axial spondyloarthritis (nr-axSpA). 
Varnost in učinkovitost adalimumaba so ocenili v dveh randomiziranih, dvojno slepih, s placebom kontroliranih študijah pri bolnikih z neradiografskim aksialnim spondiloartritisom (nr-axSpA).
Methotrexate should be continued during treatment with Hulio. 
Med zdravljenjem z zdravilom Hulio je treba še naprej uporabljati metotreksat.
• DO NOT touch this area again before giving the injection. 
• Tega predela se pred injiciranjem NE DOTIKAJTE več.
Upon completion of both studies, 383 patients enrolled in an open-label extension study, in which 40 mg adalimumab was administered every other week. 
Po koncu obeh študij so 383 bolnikov vključili v odprto nadaljevalno študijo, v kateri so bolniki dobivali 40 mg adalimumaba vsak drugi teden.
Partial Flared a Assessment of SpondyloArthritis international Society b Baseline is defined as open label baseline when patients have active disease. 
Society) b Izhodišče je določeno kot izhodišče odprte faze, ko imajo bolniki aktivno bolezen.
• signs and symptoms of infection such as fever, feeling sick, wounds, dental problems, burning on urination, feeling weak or tired or coughing; 
• znake in simptome okužbe, npr. zvišano telesno temperaturo, splošno slabo počutje, rane, težave z zobmi, pekoč občutek med uriniranjem, občutek šibkosti ali utrujenosti ali kašelj;
A patient who requires surgery while on Hulio should be closely monitored for infections, and appropriate actions should be taken. 
Bolnika, ki med zdravljenjem z zdravilom Hulio potrebuje operacijo, je treba natančno spremljati glede okužb in ustrezno ukrepati.
Available data suggest that clinical response is usually achieved within 12 weeks of treatment. 
Podatki, ki so na voljo, kažejo, da je klinični odziv ponavadi dosežen v 12 tednih zdravljenja.
If your child received Hulio while pregnant, your child's baby may be at higher risk for getting an infection for up to about five months after the last dose she received during her pregnancy. 
Če je vaš otrok prejemal zdravilo Hulio med nosečnostjo, obstaja večje tveganje, da bo dojenček vašega otroka dobil okužbo do približno pet mesecev po zadnjem odmerku, ki ga je otrok prejel med nosečnostjo.
Table 13: Efficacy Responses in Placebo-Controlled AS Study - Study I Reduction of Signs and Symptoms 
Preglednica 13: Odzivi učinkovitosti v študiji ankilozirajočega spondilitisa, kontrolirani s placebom - študija I Zmanjšanje znakov in simptomov Odziv placebo n = 107
In the pivotal controlled trials in adults and children, 12.9% of patients treated with adalimumab developed injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of patients receiving placebo or active control. 
V kontroliranih osrednjih preskušanjih pri odraslih in otrocih je reakcije na mestu injiciranja (eritem in/ali srbenje, krvavitve, bolečine ali oteklost) imelo 12,9 % bolnikov, ki so prejemali adalimumab, in 7,2 % bolnikov, ki so prejemali placebo ali primerjalno zdravilo.
The safety and efficacy of adalimumab was assessed in an open-label, multicentre study in 32 children (2 - <4 years old or aged 4 and above weighing < 15 kg) with moderately to severely active polyarticular JIA. 
Varnost in učinkovitost adalimumaba so ocenili v odprti, multicentrični študiji pri 32 otrocih (starih od 2 do < 4 leta ali starih 4 leta ali več in s telesno maso < 15 kg) z zmernim do zelo aktivnim poliartikularnim JIA.
Hulio can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), corticosteroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs). 
Zdravilo Hulio se lahko uporablja skupaj z metotreksatom ali nekaterimi imunomodulirajočimi antirevmatičnimi zdravili (sulfasalazinom, hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje), kortikosteroidi ali zdravili proti bolečinam, vključno z nesteroidnimi protivnetnimi zdravili (NSAID).
Adverse Reaction activated partial thromboplastin time prolonged), autoantibody test positive (including double stranded DNA antibody), blood lactate dehydrogenase increased 
pogosti koagulacija in motnje krvavenja (vključno s podaljšanim aktiviranim parcialnim tromboplastinskim časom), pozitiven test na prisotnost avtoprotiteles (vključno s protitelesi proti dvojnoverižni DNA), zvišanje laktat dehidrogenaze v krvi
• DO NOT twist or bend the needle cover while removing it, this may damage the needle. 
• Med odstranjevanjem pokrovčka igle NE obračajte ali prepogibajte, ker lahko poškodujete iglo.
• DO NOT move, twist, or rotate the syringe during injection. 
• Injekcijske brizge NE premikajte, sukajte ali vrtite med injiciranjem.
If your child's doctor has told you that your child has an intolerance to some sugars or if your child has been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your child's doctor before you give your child this medicine. 
Če vam je otrokov zdravnik povedal, da ima vaš otrok intoleranco za nekatere sladkorje, ali če je bila pri vašem otroku odkrita dedna intoleranca za fruktozo (HFI), redka genetska bolezen, pri kateri telo ne more razgraditi fruktoze, se posvetujte z otrokovim zdravnikom, preden otrok začne jemati to zdravilo.
• DO NOT wipe the needle or syringe. 
• NE BRIŠITE igle ali brizge.
* further information is found elsewhere in sections 4.3, 4.4 and 4.8 ** including open label extension studies 1) including spontaneous reporting data 
** Vključno pri odprtih podaljšanih študijah 1) Vključno s podatki iz spontanega poročanja
Each box contains 1 vial, 1 sterile injection syringe, 1 sterile needle, 1 sterile vial adapter and 2 alcohol pads. 
Vsaka škatla vsebuje 1 vialo, 1 sterilno injekcijsko brizgo, 1 sterilno iglo, 1 sterilen adapter za vialo in 2 alkoholna zloženca.
The recommended dose of Hulio for patients with ankylosing spondylitis axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. 
Priporočeni odmerek zdravila Hulio pri bolnikih z ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza o AS in pri bolnikih s psoriatičnim artritisom je 40 mg adalimumaba, apliciranega v enkratni subkutani injekciji vsak drugi teden.
Some of these hepatosplenic T-cell lymphomas with adalimumab have occurred in young adult patients on concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. 
Pri uporabi adalimumaba so se nekateri od teh hepatospleničnih limfomov celic T pojavili pri mladih odraslih bolnikih, ki so se sočasno zdravili z azatioprinom ali 6-merkaptopurinom, ki se uporabljata pri vnetni bolezni črevesa.
At week 4 patients were randomised to 40 mg every other week, 40 mg every week, or placebo with a total study duration of 56 weeks. 
V 4. tednu so bolnike randomizirali na 40 mg vsak drugi teden, 40 mg vsak teden ali placebo; v celoti je študija trajala 56 tednov.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INNER CARTON - VIAL MULTIPACK (WITHOUT BLUE BOX) 
PODATKI NA ZUNANJI OVOJNINI NOTRANJA ŠKATLA - VEČKRATNO PAKIRANJE VIAL (BREZ MODREGA OKENCA)
Table 14: Efficacy Response in Placebo-Controlled Study nr-axSpA I 
Preglednica 14: Odziv učinkovitosti v s placebom kontrolirani študiji nr-axSpA I
Across all treatment groups, the mean baseline PASI score was 19.7 and the baseline PGA score ranged from “mild” (<1%) to “moderate” (48%) to “severe” (46%) to “very severe” (6%). 
V vseh terapevtskih skupinah je bila povprečna izhodiščna ocena PASI 19,7, izhodiščna PGA pa je segala od ''blage'' (< 1 %), ''zmerne'' (48 %) in ''hude'' (46 %) do ''zelo hude'' (6 %).
Maintenance of clinical remission was evaluated in CD Study III (CHARM). 
Vzdrževanje klinične remisije so ovrednostili v študiji pri Crohnovi bolezni III (CHARM).
• respiratory tract infections (including cold, runny nose, sinus infection, throat infection, 
• okužbe dihal (vključno s prehladom, izcedkom iz nosu, okužbo sinusov, okužbo grla, pljučnico);
Adalimumab 40 mg every other week was assessed in 393 patients in two randomised, 24 week double-blind, placebo-controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy. 
Adalimumab 40 mg so vsak drugi teden ocenili v dveh randomiziranih, 24-tedenskih, dvojno slepih, s placebom kontroliranih študijah pri 393 bolnikih z aktivnim ankilozirajočim spondilitisom (povprečna izhodiščna ocena aktivnosti bolezni [indeks BASDAI (Bathov indeks bolezenske aktivnosti ankilozirajočega spondilitisa - Bath Ankylosing Spondylitis Disease Activity Index)] je bil v vseh skupinah 6,3), ki se niso odzvali ustrezno na konvencionalno terapijo.
If you accidentally inject your child Hulio more frequently than you should, call your child's doctor or pharmacist and explain that your child has been given more than required. 
Če ste uporabili večji odmerek zdravila Hulio, kot bi smeli Če otroku pomotoma injicirate zdravilo Hulio pogosteje, kot bi morali, se posvetujte z otrokovim zdravnikom ali farmacevtom in mu povejte, da je vaš otrok prejel večji odmerek, kot je potreben.
If you take Hulio the risk of getting lymphoma, leukaemia, or other cancers may increase. 
Če uporabljate zdravilo Hulio, se vam lahko poveča tveganje za pojav limfoma, levkemije ali drugih vrst raka.
The safety and efficacy of adalimumab were assessed in over 1,500 patients with moderately to severely active Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450) in randomised, double-blind, placebo-controlled studies. 
Varnost in učinkovitost adalimumaba so ocenili pri več kot 1500 bolnikih z zmerno do zelo aktivno Crohnovo boleznijo (indeks aktivnosti Crohnove bolezni (CDAI) ≥ 220 in ≤ 450) v randomiziranih, dvojno slepih, s placebom kontroliranih študijah.
Hulio 40 mg injection adalimumab Subcutaneous use SC 
Hulio 40 mg injekcija adalimumab subkutana uporaba s.c.